Journal: Scientific Reports
Article Title: CEACAM1 mediates B cell aggregation in central nervous system autoimmunity
doi: 10.1038/srep29847
Figure Lengend Snippet: ( A ) Gating strategy. ( B–G ) CEACAM1 expression on naïve ( B,E ) and memory B cells ( C,F ) as well as on B1 cells ( D,G ). MS patients were tested during remission ( n = 19) ( B–D ) and relapse ( n = 8) ( E–G ). Statistical significance was determined by Wilcoxon rank sum test. ( H–K ) CEACAM1/TIM-3 coexpression on B cells ( H ), cytotoxic T lymphocytes (CTLs, I ) and T helper cells (T H , J,K ) before ( J ) and after ( K ) anti-CD3/anti-CD28 antibody stimulation. Samples were analyzed from patients during remission that received treatment with natalizumab (before stimulation n = 10, after stimulation n = 8). Healthy controls ( n = 8 , n = 7) were age- and gender-matched. Patients in remission all received natalizumab ( n = 19), while patients in relapse received either natalizumab ( n = 1), interferon-β ( n = 2) or were untreated ( n = 5).
Article Snippet: PBMCs were isolated by density gradient centrifugation and stained immediately and after T cell stimulation with mouse anti-human anti-CD3 (clone CD3-2; Mabtech) and rat anti-human CD28 (clone CD28-A; Mabtech) at 0.1 μg/ml for 72 h at 37 °C and 7% CO 2.
Techniques: Expressing